Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Abstract

Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.

R F Cox and B L Waszczak
Molecular Pharmacology January 1989, 35 (1) 125-131;
R F Cox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B L Waszczak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Previous studies with (S)-(+)-N-n-propylnorapomorphine (NPA), an enantiomer of the potent dopaminergic agonist (R)-(-)-NPA, showed that this compound had a complex pharmacological profile. For example, (S)-(+)NPA had weak dopaminergic agonist potency, in that it could slow and ultimately stop firing of substantia nigra and ventral tegmental area dopamine neurons. However, antagonist properties were also evident inasmuch as immediate pretreatment with a low dose of (S)-(+)-NPA caused a significant rightward shift of the (R)-(-)-NPA dose-response curve. This dual agonist-antagonist nature of (S)-(+)-NPA suggested a low intrinsic efficacy for (S)-(+)-NPA. To test this hypothesis, we conducted dose-response studies for the inhibition of rat substantia nigra dopamine cell firing by (R)-(-)- and (S)-(+)-NPA 1 day after partial irreversible dopamine receptor inactivation with 6 mg/kg N-ethoxycarbonyl-2-ethoxy-1-2-dihydroquinoline (EEDQ) in an ethanol vehicle. This degree of inactivation resulted in a significant, parallel, rightward shift of the (R)-(-)-NPA dose-response curve relative to ethanol-treated control rats, with no loss of maximal response. After pretreatment with the same dose of EEDQ, however, the maximal response to (S)-(+)-NPA was reduced by 22% with no shift on the dose axis. The dose-response curves for control and EEDQ-treated groups were subjected to Furchgott analysis to determine per cent response versus fractional occupancy relationships for each drug. A steep hyperbolic relationship was revealed for (R)-(-)-NPA. Fifty per cent and maximal (greater than 95%) inhibitions of cell firing occurred at 3.5% and approximately 32% receptor occupancies, respectively. Hence, for (R)-(-)-NPA there is about a 68% receptor reserve in this model. The same analysis for (S)-(+)-NPA yielded an occupancy versus response plot that was more shallow and linear. Half-maximal effects occurred at 66% occupancy and the maximal response (96% inhibition) required 94% occupancy, indicating few spare receptors for (S)-(+)-NPA. Because the ratio of fractional occupancies at a given level of response is a measure of relative efficacy, we calculated a relative efficacy of (S)-(+)- to (R)-(-)-NPA of 0.05 (at the 50% response level). This confirms that (S)-(+)-NPA indeed has a much lower intrinsic efficacy than the (R)-(-)-antipode and may account for the previously reported antagonist property of the (+)-form under certain treatment conditions.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 35, Issue 1
1 Jan 1989
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.

R F Cox and B L Waszczak
Molecular Pharmacology January 1, 1989, 35 (1) 125-131;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.

R F Cox and B L Waszczak
Molecular Pharmacology January 1, 1989, 35 (1) 125-131;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics